Royalty Pharma
RPRX
RPRX
324 hedge funds and large institutions have $9.31B invested in Royalty Pharma in 2023 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 139 increasing their positions, 106 reducing their positions, and 51 closing their positions.
Holders
324
Holders Change
-9
Holders Change %
-2.7%
% of All Funds
5.11%
Holding in Top 10
8
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-20%
% of All Funds
0.13%
New
45
Increased
139
Reduced
106
Closed
51
Calls
$21.9M
Puts
$5.29M
Net Calls
+$16.6M
Net Calls Change
-$18.1M
Top Buyers
| 1 |
1
Adage Capital Partners
Boston,
Massachusetts
|
$266M |
| 2 |
2
Goldman Sachs
New York
|
$112M |
| 3 |
3
Marshall Wace
London,
United Kingdom
|
$55.5M |
| 4 |
4
Two Sigma Investments
New York
|
$34.8M |
| 5 |
5
Vanguard Group
Malvern,
Pennsylvania
|
$1.19B |
| Name | Market Value | Shares |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
SA
376
SpiderRock Advisors
Wilimington,
Delaware
| – | – | – | – |
|
377
Parallax Volatility Advisers
San Francisco,
California
| – | – | – | – |
|
378
Group One Trading
Chicago,
Illinois
| – | – | – | – |
|
|
PI
379
PEAK6 Investments
Chicago,
Illinois
| – | – | – | – |
|